General Comments / Chat, page-6438

Hi Heyline,

I am not sure if you are complaining or asking a question.
My suggestion of 2 years has nothing to do with your entry and price points.

All I can share is that it is dangerous to measure a company based on your own expectations of what the timeline should be.

IMO with research and looking what Race needs to get done, and what they typically and clearly map out for us, thanks @johndprent, my timeframe is a reasonable guess. If you seek to get out then I understand your frustration. If you believe in your investment thesis on Race then IMO you have nothing to worry about. I am tipping most on here have a trade or two at $3 or above and don't lose sleep over it.

The CR at $3 was to pay for trials in 6 areas due to be completed late this year and into early/mid 2024. Some of these trials may result in more patent work before they can be released to market. It all takes time. Daniel, Phil and team typically hit their stated timelines. Some trials may get delayed but I do not believe that will have much, if any, impact on cost.

In the ASX small and micro cap space it would difficult to find a company as well managed and have as good communications. I can't stress enough how good Race management is in trying to create value for us SHs and avoid being a lifestyle company. The whole Biotech space has been on the nose for a while along with a natural market pull back since March 2021.

I suggest you would be better off spending your time and energy looking for the next Race and getting in at a lower SP.

Good luck to you